Viacyte, a San Diego based regenerative health/drug company, set off ripples of hope and relief in the diabetes community. We’ve been dreaming of drinking coffee without blood sugar spikes, running an hour without being low for the next hour, and not having to smother my pump’s low battery alarm during meetings.
Here’s a quick review of the announcement—Viacyte is moving forward with an application, to the FDA, to initiate Phase I/II clinical trials in Type 1 diabetes patients. They’re testing safety and efficacy of an implantable device that secretes insulin through enclosed stem cells, turned to pancreatic beta cells, effectively removing the need for diabetics to take insulin. Found on Viacyte’s website, here’s their grandiose take on the product’s possibilities:
“In short, ViaCyte’s VC-01 combination product has the potential to transform the way diabetes care is managed. The product could be a virtual cure for type 1 diabetes and an important new therapy for insulin-requiring type 2 diabetes.”
